Targeted Strategies for Today's Evolving Markets

MissionIR Blog

MissionIRNewsBreaks – Sigma Labs Inc. (NASDAQ: SGLB) President, CEO Discusses Disruptive 3D Metal-Printing Technology in NNW Interview

John Rice, president and CEO of Sigma Labs (NASDAQ: SGLB), a leading developer of quality-control software for the commercial 3D-printing industry, recently discussed the company’s novel technology in a NetworkNewsAudio interview with Stuart Smith. An article discussing the company reads, “While Rice acknowledges that today ‘disruption’ is an overused term among industry practitioners and academics alike, the SGLB CEO notes that 3D printing is a disruptive technology that revolutionizes the way items — everything from consumer products to heavyweight industrial machinery — are created. SGLB technology will help reconfigure how factories operate in the future, transforming the facilities into Internet of Things factories that will be redesigned along the entire value chain, he says. . . . Among other industries, additive laser powder-bed manufacturing (or 3D metal printing) is recognized as a disruptive technology that can considerably enhance all of manufacturing, especially the defense industry’s operations and military capabilities. Offering solutions such as unmanned and autonomous robotic systems, directed-energy weapons, human-performance modification and cyber capabilities, 3D printing is set to transform warfare.”

To view the full article, visit http://ibn.fm/Wh7Bk

About Sigma Labs Inc.

Sigma Labs is a leading provider of quality-assurance software to the commercial, 3D-printing industry under the PrintRite3D(R) brand. Founded in 2010, Sigma is a software company that specializes in the development and commercialization of real-time, computer-aided inspection (CAI) solutions known as PrintRite3D for 3D advanced-manufacturing technologies. Sigma Labs’ advanced, computer-aided, software product revolutionizes commercial additive manufacturing, enabling nondestructive quality assurance mid-production and uniquely allowing errors to be corrected in real time. For more information, visit the company’s website at www.SigmaLabsInc.com.

NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://ibn.fm/SGLB

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in MissionIRNewsBreaks, Sigma Labs Inc. SGLB | Leave a comment

MissionIRNewsBreaks – Zacks Small Cap Research Issues Update, Maintains Price Target on Pressure BioSciences Inc. (PBIO)

Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables and platform-technology solutions to the life sciences and other industries, was recently covered in a research report by Zacks Small Cap Research, a division of Zacks Investment Research. Among other highlights, Zacks maintained its $4.44 share price target on shares of PBIO. An article discussing the company reads, “The Zacks report (http://ibn.fm/z1W3H) points to demand that ‘is expected to accelerate starting in 2020,’ which nonetheless follows many years of consistent yearly revenue increases by PBIO. The company itself is standing by its stated anticipation of doubling revenue in 2020, due to expected sales of their soon-to-be-released $200,000 BaroShear K45 systems. These new instrument systems utilize PBI’s proprietary Ultra Shear Technology(TM) (UST) platform to effectively produce high-quality, long-term stable, water-soluble nanoemulsions of CBD oil (http://ibn.fm/PFora).”

To view the full article, visit http://ibn.fm/vSmuE

About Pressure BioSciences Inc.

Pressure BioSciences is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. The company’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented, enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). PBIO’s primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of its pressure-based technologies in the following areas: (1) the use of its recently acquired, patented technology from BaroFold Inc. (the “BaroFold” technology) to allow entry into the biopharma contract services sector, and (2) the use of its recently patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room-temperature, stable low-acid liquid foods that cannot be effectively preserved using existing nonthermal technologies. For more information, visit the company’s website at www.PressureBiosciences.com.

NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.htm

Posted in MissionIRNewsBreaks, Pressure BioSciences Inc. PBIO | Leave a comment

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Expects Sustainable Revenue Growth, Plans New Capital Markets Strategy in 2020

  • Growing interest in the company’s innovative DehydraTECH™ drug delivery platform from large global corporations
  • Lexaria’s strategy to be listed on a nationally recognized U.S. exchange will help the company access a significantly larger audience of investors
  • Lexaria has 16 patents with another 60 pending worldwide and is the only company to hold a patent for improved delivery of all non-psychoactive cannabinoids

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a global innovator in drug-delivery platforms, has achieved virtually everything it set out to do in 2019 and has even bigger plans for 2020 that include achieving higher revenue and being listed on a major U.S. exchange, according to CEO Chris Bunka in a strategic update to shareholders (http://ibn.fm/zA8bd). While its shares remain “dramatically undervalued” at the moment, Bunka said, the company boasts a successful 2019 during which it signed different partnerships and agreements for use of its innovative DehydraTECH™ drug delivery platform.

The revolutionary drug delivery platform accelerates human intestinal cell absorption of bioactive substances administered without the need for inhalational dosing, co-administration with sugars or sweeteners, and other unhealthy practices. It is applicable to a wide variety of bioactive substances, including cannabis and nicotine. The innovative technology makes it possible to deliver bioactive substances via oral ingestion bypassing potentially unhealthy and unsafe practices. It has been shown to accelerate CBD absorption by 499 percent and achieve a CBD blood concentration 319 percent higher than traditional formulation.

The company developed its platform based on recognition of the fact that inhalation poses certain risks. Edible ingestion makes it possible to absorb a substance in a healthier and safer way. The platform has also been proven to deliver up to 10 times more of active ingredients in comparison to traditional edibles. DehydraTECH™ is the first platform of its kind that allows users to access the primary benefits of inhalation – speed and efficiency – while circumventing the risks of inhalation.

Lexaria Bioscience currently has 16 patents granted and more than 60 patent applications worldwide and is the only company to hold a patent for improved delivery of all cannabinoids and nicotine. According to Bunka, one of the company’s biggest achievements in 2019 was receiving the first ever patents to use DehydraTECH™ with cannabinoids for the treatment of Alzheimer’s, Parkinson’s, schizophrenia and heart disease, in Australia. Lexaria is working to gain fast-track patent status for the same health conditions in the U.S. this year, which will allow the company to achieve one of its goals for 2020 – developing relationships in the pharmaceutical industry, as well.

In 2019, the company also finalized a new contractual relationship with a GMP-certified, FDA registered production company to get enhanced DehydraTECH™ powders to market in the U.S. with current capacity of roughly 200,000 servings per day. According to Bunka, this can increase to 400,000 servings per day within the same facility. “Lexaria is experiencing strong demand from many companies requesting pre-processed DehydraTECH-enhanced bulk powders for their specific product lines and with this facility, we can meet that demand,” he said in a news release.

In 2020, the company expects to more than double its entire 2019 revenue from existing clients in the context of a projected sustainable revenue growth all throughout the year and beyond by leveraging a rich pipeline of prospective additional clients to be onboarded the following months, Bunka explained. “One of our existing U.S. clients is embarking on an aggressive growth strategy from their home state to several additional states within the next year. Another existing U.S. client is in the next 90 days launching their bottled beverage with CBD and DehydraTECH technology within, generating first-ever revenue for Lexaria during Q1,” Bunka continued.

This revenue increase will support the company’s own future growth plans. To increase its market visibility and ultimately expand its customer base, Lexaria Bioscience plans to dramatically alter its capital markets strategy this year to qualify for listing on a nationally recognized U.S. exchange. The company has already met with several Wall Street investment banking firms for this purpose. Listing on a major U.S. exchange would allow Lexaria Bioscience access to a significantly larger audience of investors and open a path to a growing number of more lucrative strategic opportunities, Bunka concluded.

For more information, visit the company’s website at www.LexariaBioscience.com

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Lexaria Bioscience Corp. (LXRP) | Leave a comment

Concerns About Vape Addiction, Injury Provide Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) with Opportunity

  • Lexaria Bioscience continues to advance the effectiveness of its proprietary DehydraTECH technology, a formulation that teams with drug substances such as nicotine and cannabidiol to quickly carry those drugs into a user’s blood stream
  • Recent concerns about the safety of vape products and ongoing concerns about the safety of tobacco are opening doors to Lexaria’s edible technology
  • Newly legalized cannabis-infused edibles began hitting store shelves nationwide in Canada last month, presenting Lexaria with new potential licensing outlets for its increasingly effective products

If 2019 was the year when vape users discovered the potential perils of using untested off-brand products, 2020 may well be the year when vape users share the common woe of struggling to beat an addiction.

The U.S. Centers for Disease Control and Prevention (CDC) reported at year’s end that 2,561 people had been hospitalized with the vape-related lung illness now known as ‘e-cigarette or vaping product use-associated lung injury’ (EVALI) as of December 27, that the illness had afflicted every U.S. state and two territories, and that 55 EVALI-related deaths had been confirmed in 27 states and the District of Columbia, with the incidence of new cases in decline (http://ibn.fm/mh8Ga).

With the advent of the new year, anti-youth vaping advocacy group Truth Initiative reported (http://ibn.fm/ZmCUn) a survey that showed “nearly half of young people are looking to quit vaping as their New Year’s resolution.” Many parents find themselves fighting back fears of the potential outcomes as they see their children drawn into addictive behaviors (http://ibn.fm/XooYb).

Oral drug product innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is a company dedicated to the concept that there are better alternative methods for drug substance use than inhalation. The British Columbia-based bio-delivery technology developer patented its DehydraTECH™ oral drug delivery technology and has been continuing to advance its ability to pair the IP with substances such as nicotine and cannabidiol (CBD) for access to users’ bloodstreams at rapid rates comparable to the speed of acquisition by inhalation.

Swallowed medications have historically been slower to provide effective action than inhaled ones, leading substance users looking for a quick fix to lean toward the latter. But the deleterious and deadly consequences of smoking tobacco products have been publicly acknowledged for decades, though hardly stemming the tide of nicotine addiction as one generation succeeds another.

The continued preference for the rapid delivery of inhaled drug substances has led many researchers to seek alternatives beyond deterrence campaigns. DehydraTECH’s newest formulation was recently shown to deliver to deliver 811 percent more CBD into the bloodstream than generic industry control formulations, nearly doubling the capacity of existing DehydraTECH technology. It was additionally shown to deliver 1,937 percent more CBD across the blood-brain barrier into brain tissue than generic industry control formulations and 487 percent more than the original DehydraTECH technology (http://ibn.fm/YEn9J).

The blood-brain barrier is a natural biological system of blood vessels and endothelial cells that bar nearly all small-molecule drugs from accessing the brain’s central nervous system hierarchy and finding the ability to defeat it has been a primary concern for medical product developers.

The potential applications of Lexaria’s technology are many. Perhaps most noticeable at the moment is the uses arising from the legalization of cannabis-infused food on a national basis in Canada, with the first products in store shelves as of last month (http://ibn.fm/k0GHu), but the technology also creates the potential for vape makers to offer non-inhaled products to shore up their marketing.

The company has begun licensing its technology to a variety of other producers in the cannabis and tobacco spaces. Lexaria’s licensed in-house research laboratory and its IP portfolio have developed 16 patents with over 60 patents pending worldwide.

For more information, visit the company’s website at www.LexariaBioscience.com

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Lexaria Bioscience Corp. (LXRP) | Leave a comment

Sigma Labs Inc. (NASDAQ: SGLB) Strives to Help Aerospace Manufacturers Overcome 3D Quality Manufacturing Problems

  • 3D-printed weight-optimized and flow-optimized parts significantly improve the performance of aircraft and rockets
  • Global aerospace 3D-printing market estimated at $1.4 billion in 2018, projected to reach $6.8 billion by 2026
  • Sigma Labs’ breakthrough quality-assurance solution PrintRite3D® set to revolutionize 3D-printing industry, enabling it to grow globally

Sigma Labs Inc. (NASDAQ: SGLB) is set to exploit the tremendous aerospace 3D-printing-market growth potential with its revolutionary in-process, quality-assurance technology. This technology is poised to help the industry scale a critical hurdle: ensuring effective and efficient quality in real time.

The global aerospace 3D-printing market was estimated at $1.4 billion in 2018, projected to reach $6.8 billion by 2026 with an expected CAGR in excess of 22% during the forecast period. The airline and spacecraft segment is expected to lead the aerospace 3D-printing market due to the need for low-volume, low-weight parts that can be manufactured using 3D-printing technologies, which reduces supply chain constraints, minimizes warehouse space and lowers waste materials compared to traditional manufacturing processes (http://ibn.fm/oXjCV).

As the industry is challenged by environmental restrictions, high manufacturing cost and a competitive market environment, 3D metal components manufacturing offers a unique solution to help overcome much of these challenges.

Weight is considered the most important feature in the design and development of an aircraft because of its tremendous impact on fuel consumption. 3D-printing technology can help build lighter fuel-saving aircraft parts, a characteristic essential in an industry that operates at low-profit margins. Additive manufacturing provides advanced manufacturing techniques for developing the components, parts while maintaining the strength and aerodynamic features of an aircraft. This is an important motivating factor for airlines to procure newer generation aircraft, which will drive the growth of the additive-manufacturing sector. The aircraft segment currently holds the major share in 3D printing for the aerospace and defense market.

3D-printing technology also provides companies with a critical competitive advantage as it offers the flexibility to design and test products multiple times and quickly build prototypes, helping companies to cost effectively reduce uncertainties and improve the functionality of their products, thereby accelerating design cycles and reducing time to market.

By making the production process of components faster, cheaper, and simpler, while also enabling the seamless integration of components into a single structure and reducing the need for external joints, fasteners and adhesives, additive manufacturing has attracted interest from major aircraft manufacturers such as Boeing and Airbus B.V. as well as component producers such as Rolls-Royce, Pratt & Whitney and GE Aviation.

However, 3D-printing technology is facing a significant technical hurdle: real-time process monitoring and control. Due to variability in the 3D-printing process, consistent quality of produced parts is not reliably achieved without postproduction inspection, which is time consuming, costly and results in high rejection costs. Since components and parts can currently be inspected only by CT scans and other means, the producer doesn’t know until the end of the process if the finished parts meet design specifications, resulting in lost time and profits as well as the inability to economically scale up production.

Sigma Labs is revolutionizing the traditional quality assurance process with its quality-assurance software that operates in real-time, in process as parts are being formed unlike any other quality-assurance software on the market, Sigma Labs’ PrintRite3D® is a unique third-party validated software that enables real-time monitoring, analysis, feedback and control during the 3D-printing process of precision metal parts. PrintRite3D detects defects during the production process while providing feedback to machine operators allowing corrective actions to be taken, leading to faster production of metal parts with fewer errors and a more uniform product. Users will realize results in decreased downtime and waste while increasing yield and profits for 3D-printing companies.

Compared to its competitors, Sigma Labs’ PrintRite3D provides users with a superior solution. Most other solutions do not offer features such as crucial calibration filters, raw data export, machine-learning-enabled automated anomaly detection, and 3D thermal data visualization. Within the rapidly growing aerospace sector, Sigma Labs has been recognized as a superior solution to the industry’s critical needs and, as such, was selected by the industry-leading producer Airbus earlier this year to deploy its PrintRite3D Rapid Test and Evaluation Program.

With tier-1 clients such as Airbus, Siemens, Pratt & Whitney and Honeywell evaluating the software, Sigma Labs is on a clear path to grow significantly in 2020. The company is uniquely positioned to capture a significant part of the sizable addressable market with its proprietary technology that enables the entire 3D-metal-printing industry to overcome the single most-significant barrier to adoption in serial production.

For more information, visit the company’s website at www.SigmaLabsInc.com

NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://ibn.fm/SGLB

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Sigma Labs Inc. SGLB | Leave a comment

MissionIRNewsBreaks – Jerrick Media Holdings Inc. (JMDA) CEO Details Company’s Patience, Discipline and Hard Work in Weekly Update

Jerrick Media Holdings (OTCQB: JMDA), a holding company that gives technology products the resources and opportunities to make ideas a reality, recently published a weekly update from the company’s CEO Jeremy Frommer. In the update, Frommer discussed that, early into the new year, the company is off to a promising start and continues to work through multiple tracks. These include S-1 and NASDAQ application paperwork, raising capital and growing revenues, as well as controlling costs to develop an important proprietary technology platform with tremendous present and future value. “There is a symphony of moving parts to pull off the uplist, all of which essentially come down to our continued patience, discipline and hard work,” Frommer states in the update.

To view the full update, visit http://ibn.fm/lJrCn

About Jerrick

Jerrick is a holding company that develops technology-based solutions. The company’s flagship product Vocal is a long-form, digital, publishing platform focused on supporting content creators by providing them with publishing tools and monetization features that are embedded within digital communities. Vocal is architected to enable targeted marketing of branded content and e-commerce opportunities embedded within long-form content. Vocal’s community sites are managed by a dedicated team, whose primary focus is on creating safe communities and identifying monetization opportunities within those communities. For more information, visit the company’s website at https://Jerrick.media.

NOTE TO INVESTORS: The latest news and updates relating to JMDA are available in the company’s newsroom at http://ibn.fm/JMDA

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Jerrick Media Holdings Inc. JMDA, MissionIRNewsBreaks | Leave a comment

ChineseInvestors.com Inc. (CIIX) Continues Focus on Investor Education, CBD Biotech; Anticipates Profitable New Year

  • Maximizing profit by creating, leveraging products with 10-to-20x profitability margins
  • Investors encouraged to review CBD Biotech’s impressive product line, strategic plan for revenue increase.
  • Driving growth in new year with growing demand for CBD products

ChineseInvestors.com Inc. (OTCQB: CIIX) is a leading financial-information website for Chinese-speaking investors in the United States and China. CIIX CEO Warren Wang recently discussed the company’s goals and bright outlook for 2020 during a MoneyTV.net interview with Donald Baillargeon (http://ibn.fm/PlWY7).

The new year looks promising for CIIX, Wang stated. Using Chinese language character sets, the company offers investor-education products and services, real-time market commentary, analysis and educational-related services as well as advertising, public-relations-related support services and consultative services to smaller private companies.

In addition to financial services, the company has invested in the growing demand for cannabidiol (CBD)-based nutrition and health products. An IPO of CIIX’s wholly owned foreign enterprise, CBD Biotech, is anticipated early this year (http://ibn.fm/q0Ycx). In his interview, Wang gave an overview of CBD Biotech’s impressive product line, and he urged investors to do likewise in order to grasp the company’s plan to achieve profitability.

CBD Biotech’s major asset is its 40,000 repeat customers, said Wang, who discussed a B2C division of the company whose purpose is to target these consumers through telemarking and social media. The goal is to see how to retain this targeted group and keep these customers coming back. In addition, a separate CBD Biotech B2B division is working to maximize revenue to wholesalers. The two divisions have the same goals: increase sales, lower costs and maximize profitability.

Regarding stock price, Wang pointed out the hard work of employees, the company’s revenue, and the quality of the product line and profit margins as he shared with investors his confidence in the future of CIIX. CBD cosmetics products have a 10-to-20x profit margin, Wang noted, as he explained that the CBD cosmetic product line will be a vital part of driving growth as the company works to lower costs and maximize profitability. The company achieved almost $5 million in revenue during calendar year 2019, Wang said, and he expressed his optimism regarding the upcoming year as well.

In an earlier interview with Baillargeon (http://ibn.fm/iAVOP), Wang emphasized the bright future of the hemp/CBD industry in China, which has four times the market potential of America. CBD Biotech is one of the first companies to enter the industry, solidifying its place as a big player in the future of cannabis in China.

Last year was a successful year for CIIX, and Wang is looking forward to continued profitability and successful in 2020 as the company works toward an even more stable future.

For more information, visit the company’s website at www.ChineseInvestors.com

NOTE TO INVESTORS: The latest news and updates relating to CIIX are available in the company’s newsroom at  http://ibn.fm/CIIX

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Chineseinvestors.com, Inc. CIIX | Leave a comment

MissionIRNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Announces Agreement to Provide DehydraTECH(TM) Technology to Cannadips CBD

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, this morning announced that it has reached a definitive agreement to provide its patented DehydraTECH(TM) technology to Cannadips CBD, the Original Smokeless CBD Dip Brand. According to the update, each tin of Cannadips contains 15 pouches, each with 10mg of hemp-derived CBD, and includes only natural sweeteners with no tobacco or nicotine. Already established as the leader in CBD oral delivery, Lexaria has been working behind the scenes with the Boldt Runners team to elevate the product experience. “In our quest to create the ultimate smokeless, oral cannabinoid experience for our customers, we found that the DehydraTECH technology solves many challenges and propels the product forward as we pioneer this product category,” The Boldt Runners Corporation Founder and Chief Executive Officer Case Mandel said  in the news release. “Through our strong distribution partnership with Kretek International, and our family of strategic retail partners including Sheetz, Kwiktrip, and Circle K we are stoked for the DehydraTECH technology to shine through our tins.”

To view the full press release, visit http://ibn.fm/Z7H1l

About Lexaria Bioscience Corp.

Lexaria Bioscience is a global innovator in drug-delivery platforms. The company’s patented DehydraTECH drug-delivery technology changes the way active pharmaceutical ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. DehydraTECH increases bioabsorption, reduces time of onset and masks unwanted tastes for orally administered bioactive molecules including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (“NSAIDs”), nicotine and other molecules. Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry for use in cannabinoid beverages, edibles and oral products, as well as to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed, in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Lexaria Bioscience Corp. (LXRP), MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Why Jerrick Media Holdings Inc. (JMDA) Is ‘One to Watch’

Jerrick Media Holdings (OTCQB: JMDA) is a holding company concentrating on the advancement of digital communities, targeted marketing of branded digital content and e-commerce opportunities. Vocal, the company’s flagship product, is a proprietary, long-form, digital publishing platform. A recent article discussing the company reads, “Designed to develop and cost-effectively engage content creators, the Vocal platform enables its over 500,000 registered content creators to reach an engaged audience and monetize their content. In addition to providing relevant content, Vocal’s technology is centered on efficiency and scalability through its niche digital communities, as well as output through its data-driven distribution strategy. . . . Vocal partners with content creators and brands that recognize difficulties inherent in the digital advertising space and that can benefit from branded content marketing opportunities available on publishing platforms like Vocal.”

To view the full article, visit http://ibn.fm/igDnb

About Jerrick

Jerrick is a holding company that develops technology-based solutions. The company’s flagship product Vocal is a long-form, digital, publishing platform focused on supporting content creators by providing them with publishing tools and monetization features that are embedded within digital communities. Vocal is architected to enable targeted marketing of branded content and e-commerce opportunities embedded within long-form content. Vocal’s community sites are managed by a dedicated team, whose primary focus is on creating safe communities and identifying monetization opportunities within those communities. For more information, visit the company’s website at https://Jerrick.media.

NOTE TO INVESTORS: The latest news and updates relating to JMDA are available in the company’s newsroom at http://ibn.fm/JMDA

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Jerrick Media Holdings Inc. JMDA, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH Platform Boosts CBD Absorption Levels

Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) innovative DehydraTECH(TM) delivery platform is patented for all nonpsychoactive cannabinoids as well as for tetrahydrocannabinol (THC) and psychoactive cannabinoids. An article discussing the company reads, “Medical researchers have struggled to find ways to penetrate the blood brain barrier effectively to transport beneficial drugs for many years. This barrier exists to block toxic or otherwise dangerous substances from entering the brain and is formed by layers of microvascular endothelial cells inside blood vessels. Lexaria’s DehydraTECH(TM) drug delivery platform brings beneficial drugs to the brain faster. . . . In June 2019, Lexaria completed a series of animal studies using an enhanced formulation of its DehydraTECH technology. This series built on the company’s original, independent, third-party laboratory in vitro lab experiments began in 2015, which showed utilization of the DehydraTECH drug-delivery platform increased the absorption levels of cannabidiol (CBD) in human intestinal cells by an impressive 499%. The results of the studies showed delivery of 1,937% more CBD into animal brain tissue after eight hours using the enhanced DehydraTECH technology in comparison with generic industry MCT coconut-oil formulations. Moreover, the animal studies using the enhanced formulation showed an 811% increase of CBD delivery into the blood in comparison with generic MCT coconut-oil formulations.”

To view the full article, visit http://ibn.fm/GKJPP

About Lexaria Bioscience Corp.

Lexaria Bioscience is a global innovator in drug-delivery platforms. The company’s patented DehydraTECH drug-delivery technology changes the way active pharmaceutical ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. DehydraTECH increases bioabsorption, reduces time of onset and masks unwanted tastes for orally administered bioactive molecules including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (“NSAIDs”), nicotine and other molecules. Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry for use in cannabinoid beverages, edibles and oral products, as well as to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed, in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Lexaria Bioscience Corp. (LXRP), MissionIRNewsBreaks | Leave a comment